Actinium Pharmaceuticals
6 clinical trials · Sponsor
◉ Watch Actinium Pharmaceuticals
| Record | Firm | Date |
|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML (NCT07157514) | Actinium Pharmaceuticals | 2026-01-01 |
| Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients (NCT03932318) | Actinium Pharmaceuticals | 2023-03-01 |
| Venetoclax and Lintuzumab-Ac225 in AML Patients (NCT03867682) | Actinium Pharmaceuticals | 2020-01-15 |
| A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma (NCT02998047) | Actinium Pharmaceuticals | 2016-12-01 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (NCT02665065) | Actinium Pharmaceuticals | 2016-06-01 |
| Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (NCT02575963) | Actinium Pharmaceuticals | 2012-10-01 |
Track Actinium Pharmaceuticals automatically
Every clearance here is in the API, with alerts when new ones post.